Provided by Tiger Trade Technology Pte. Ltd.

Savara Inc

5.53
-0.0600-1.07%
Volume:912.10K
Turnover:5.03M
Market Cap:1.13B
PE:-9.56
High:5.60
Open:5.60
Low:5.43
Close:5.59
52wk High:7.01
52wk Low:3.08
Shares:204.66M
Float Shares:198.20M
Volume Ratio:0.52
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5782
EPS(LYR):-0.5344
ROE:-105.48%
ROA:-50.15%
PB:7.88
PE(LYR):-10.35

Loading ...

Savara Inc: Prescription Drug User Fee Act (Pdufa) Target Action Date Extended by Three Months to November 22, 2026

THOMSON REUTERS
·
Apr 16

Savara presents new Phase 3 IMPALA-2 molgramostim data at ATS 2026

Reuters
·
Apr 14

Savara announces annual shareholder meeting via webcast

Reuters
·
Apr 11

BUZZ-Savara rises as UK accepts application for rare lung disease drug

Reuters
·
Apr 07

Savara Announces The U.K. Medicines And Healthcare Products Regulatory Agency (Mhra) Has Accepted The Molbreevi* Marketing Authorisation Application (Maa) For Autoimmune Pulmonary Alveolar Prote

Reuters
·
Apr 07

Savara publishes corporate presentation highlighting MOLBREEVI autoimmune PAP Phase 3 data

Reuters
·
Apr 07

Savara announces MHRA accepted submission of Molbreevi MAA

TIPRANKS
·
Apr 07

Savara says UK MHRA accepts Molbreevi filing for autoimmune PAP under accelerated review

Reuters
·
Apr 07

Savara Inc - Mhra Decision on Molbreevi Maa Expected in Q4 2026

THOMSON REUTERS
·
Apr 07

Savara Announces the U.k. Medicines and Healthcare Products Regulatory Agency (Mhra) Has Accepted the Molbreevi* Marketing Authorisation Application (Maa) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

THOMSON REUTERS
·
Apr 07

Savara Inc - FDA Pdufa Date for Molbreevi Bla Set for August 22, 2026

THOMSON REUTERS
·
Apr 07

A Look At Savara (SVRA) Valuation As MOLBREEVI Nears Key Regulatory Decisions In Rare Lung Disease

Simply Wall St.
·
Apr 01

Savara publishes corporate presentation spotlighting MOLBREEVI Phase 3 progress in autoimmune PAP

Reuters
·
Mar 30

Savara announces EMA validation of MAA for MOLBREEVI

TIPRANKS
·
Mar 30

Savara says EMA validates MOLBREEVI marketing application for autoimmune PAP

Reuters
·
Mar 30

Savara Inc - Molbreevi Bla Under FDA Priority Review With August 22, 2026 Action Date

THOMSON REUTERS
·
Mar 30

Savara Announces European Medicines Agency (Ema) Validation of Marketing Authorization Application (Maa) for Molbreevi* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

THOMSON REUTERS
·
Mar 30

Savara Inc - Ema Review of Molbreevi Maa Initiated, Decision Expected in Q1 2027

THOMSON REUTERS
·
Mar 30

Savara (SVRA) Gets a Buy from LifeSci Capital

TIPRANKS
·
Mar 21

Savara Q4 Loss Unchanged From Year Earlier

MT Newswires Live
·
Mar 13